Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Capital Expenditures for 3 consecutive years, with $31000.0 the latest figure, recorded in Q3 2025.

• In Q3 2025, Capital Expenditures fell 99.07% year-over-year to $31000.0; the TTM figure through Dec 2025 stood at $31000.0 (down 98.81% YoY), while the FY2025 annual figure was $31000.0, down 98.81% from the prior year.
• Capital Expenditures climbed to $31000.0 in Q3 2025 per INBX's latest filing, from -$21000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.4 million in Q4 2023 and bottomed at -$951000.0 in Q4 2024.
• Historically, Capital Expenditures has averaged $802333.3 across 3 years, with a median of $31000.0 in 2025.
• On a YoY basis, Capital Expenditures climbed as much as 190.27% in 2024 and fell as far as 127.63% in 2024.
• Inhibrx Biosciences' Capital Expenditures stood at $3.4 million in 2023, then slumped by 127.63% to -$951000.0 in 2024, then soared by 103.26% to $31000.0 in 2025.
• Business Quant data shows INBX's Capital Expenditures at $31000.0 in Q3 2025, -$21000.0 in Q2 2025, and $21000.0 in Q1 2025.